Physician profile
Eric Teller
NPI 1700097326
$216,604.93
in general payments reported to CMS, 2019-2025
43 companies · $38K in 2025
The $38K reported for 2025 was more than what 98% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,061 · 2020: $14K · 2021: $40K · 2022: $31K · 2023: $36K · 2024: $56K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112K · Food and Beverage: $14K · Travel and Lodging: $2,034 · Education: $718 · Consulting Fee: $635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111,504.00 |
| Food and Beverage | $14,386.95 |
| Travel and Lodging | $2,033.50 |
| Education | $718.49 |
| Consulting Fee | $634.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $127,393.85 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Genzyme Corporation | $35,492.39 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $20,808.31 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $12,774.20 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Idorsia Pharmaceuticals US INC | $4,954.77 | 2022-2023 | Quviviq |
| Amgen INC. | $2,147.60 | 2022-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,119.69 | 2019-2025 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Jazz Pharmaceuticals INC. | $1,634.76 | 2019-2025 | Xywav |
| Insmed, INC. | $1,594.24 | 2019-2025 | Arikayce, Brinsupri |
| Mallinckrodt Hospital Products INC. | $1,160.19 | 2020-2025 | Acthar |
| Harmony Biosciences LLC | $1,106.26 | 2020-2025 | Wakix |
| Mylan Specialty L.P. | $681.37 | 2019-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $663.35 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $542.67 | 2022-2024 | Uptravi, Opsumit |
| Teva Pharmaceuticals USA, INC. | $377.48 | 2019-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $367.47 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Sanofi-Aventis U.S. LLC | $288.95 | 2021-2023 | |
| Inspire Medical Systems, INC. | $273.84 | 2024-2025 | Inspire |
| Advanced Respiratory, INC | $264.50 | 2020-2021 | |
| Genentech USA, INC. | $248.32 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $220.60 | 2019-2022 | |
| Grifols USA, LLC | $218.40 | 2022-2025 | Prolastin-C Liquid |
| Eisai INC. | $211.87 | 2020-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $146.05 | 2024-2025 | Lumryz |
| Baxter Healthcare | $129.36 | 2022-2024 | Hillrom - Life 2000 Ventilation System |
| Novartis Pharmaceuticals Corporation | $121.60 | 2019-2024 | |
| Electromed, INC. | $91.85 | 2021-2022 | |
| Axsome Therapeutics, INC. | $82.77 | 2023 | Sunosi |
| United Therapeutics Corporation | $79.76 | 2024-2025 | Tyvaso, Tyvaso |
| Paratek Pharmaceuticals, INC. | $69.62 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $47.30 | 2019 | |
| 3b Medical, INC. | $39.29 | 2023-2025 | Luna |
| Circassia INC. | $33.84 | 2019 | |
| Pulmonx Corporation | $33.66 | 2022 | |
| Verona Pharma, INC. | $31.44 | 2025 | Ohtuvayre |
| Itamar Medical INC | $27.75 | 2021 | |
| Pfizer INC. | $21.93 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.92 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.24 | 2021 | |
| Alexion Pharmaceuticals, INC. | $19.17 | 2025 | Ultomiris |
| Resmed Corp | $16.22 | 2025 | |
| Lilly USA, LLC | $14.97 | 2025 | Zepbound |
| Viatris Specialty LLC | $14.11 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Teller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.